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Abstract
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Background—Cannabis use disorder (CUD) is a prevalent and impairing condition, and
established psychosocial treatments convey limited efficacy. In light of recent findings supporting
the efficacy of N-acetylcysteine (NAC) for CUD in adolescents, the objective of this trial was to
evaluate its efficacy in adults.
Methods—In a 12-week double-blind randomized placebo-controlled trial, treatment-seeking
adults ages 18–50 with CUD (N=302), enrolled across six National Drug Abuse Treatment
Clinical Trials Network-affiliated clinical sites, were randomized in a 1:1 ratio to a 12-week course
of NAC 1200 mg (n=153) or placebo (n=149) twice daily. All participants received contingency
management (CM) and medical management. The primary efficacy measure was the odds of
negative urine cannabinoid tests during treatment, compared between NAC and placebo
participants.

Author Manuscript

Results—There was not statistically significant evidence that the NAC and placebo groups
differed in cannabis abstinence (odds ratio = 1.00, 95% confidence interval 0.63 – 1.59; p=0.984).
Overall, 22.3% of urine cannabinoid tests in the NAC group were negative, compared with 22.4%
in the placebo group. Many participants were medication non-adherent; exploratory analysis
within medication-adherent subgroups revealed no significant differential abstinence outcomes by
treatment group.
Conclusions—In contrast with prior findings in adolescents, there is no evidence that NAC 1200
mg twice daily plus CM is differentially efficacious for CUD in adults when compared to placebo
plus CM. This discrepant finding between adolescents and adults with CUD may have been
influenced by differences in development, cannabis use profiles, responses to embedded
behavioral treatment, medication adherence, and other factors.
Keywords
cannabis; marijuana; addiction; treatment; cessation; pharmacotherapy; N-acetylcysteine

Author Manuscript

1. Introduction
One in eleven adult cannabis users develops cannabis use disorder (CUD), a syndrome with
well characterized physiological and behavioral symptoms and associated adverse outcomes
(Budney and Moore, 2002; Hasin et al., 2015; Volkow et al., 2014). CUD is prevalent, with
2.5% United States adults meeting criteria in the past year, but only 13.2% of those with
lifetime CUD participate in any treatment for the disorder (Hasin et al., 2016). For those
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who do, evidence-based psychosocial interventions yield modest effects, with few
individuals achieving long-term cannabis abstinence, though some evidence suggests that
the behavioral intervention contingency management (CM), in which tangible incentives are
provided for desired behaviors (e.g., objective indicators of cannabis abstinence) may
enhance outcomes (Cooper et al., 2015; Gates et al., 2016). Amid increased understanding
of the neuropharmacology of CUD, recent efforts have focused on developing
pharmacotherapies to complement psychosocial treatments (Copeland and Pokorski, 2016;
Marshall et al., 2014). N-acetylcysteine (NAC), available over-the-counter as an antioxidant
supplement, restores glutamate homeostasis and reduces reinstatement of drug seeking in
animal models of addiction and is being evaluated clinically as a potential treatment for a
variety of substance use disorders (Baker et al., 2003; McClure et al., 2014). In an 8-week
randomized placebo-controlled trial (RCT) for CUD in adolescents ages 15–21 (N=116)
receiving a CM intervention and weekly medical clinician-delivered cessation counseling,
NAC compared to placebo more than doubled the odds of abstinence during treatment,
reflected in negative weekly urine cannabinoid tests (OR=2.4, 95% CI: 1.1–5.2, p=0.029)
(Gray et al., 2012). While these positive findings were encouraging, a similar trial in adults
was deemed necessary to evaluate efficacy in this age group. The present study was designed
to replicate and extend the adolescent study’s general methods via a 12-week RCT (McClure
et al., 2014). We hypothesized that NAC-treated adults would evidence higher rates of
abstinence during treatment than those receiving placebo.

2. Material And Methods
2.1 Trial Design

Author Manuscript

Treatment-seeking adults with CUD were randomized, in 1:1 parallel group allocation, to
receive a double-blind 12-week course of NAC (1200 mg) or placebo twice daily, added to a
CM intervention and medical clinician-delivered medical management. Urine specimens
were collected at baseline, twice weekly throughout treatment, at end-of-treatment, and at
post-treatment follow-up for urine cannabinoid testing (UCT) by dipstick, and an aliquot
was collected once a week for enzyme immunoassay (Abbott Laboratories, Chicago, IL)
analysis by a central laboratory (Clinical Neurobiology Laboratory, Medical University of
South Carolina, Charleston SC) for the primary outcome.

Author Manuscript

The study was conducted within an approved United States Food and Drug Administration
Investigational New Drug application. The institutional review boards at participating
centers approved the study protocol, which was overseen by an independent National
Institute on Drug Abuse-appointed Data and Safety Monitoring Board. All participants
provided written informed consent.
The trial was implemented across six sites within the National Drug Abuse Treatment
Clinical Trials Network (CTN): Behavioral Health Services of Pickens County, Pickens,
South Carolina; CODA, Portland, Oregon; University of California Los Angeles Integrated
Substance Abuse Programs, Los Angeles, California; APT Foundation, New Haven,
Connecticut; University of Texas Health Science Center San Antonio, San Antonio, Texas;
University of Kentucky, Lexington, Kentucky.

Drug Alcohol Depend. Author manuscript; available in PMC 2018 August 01.

Gray et al.

Page 4

2.2 Participants
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The trial enrolled treatment-seeking participants ages 18–50 meeting Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria for
cannabis dependence and submitting a positive UCT during the initial screening visit (Figure
1) (American Psychiatric Association, 2000). Individuals with acutely unstable medical or
psychiatric disorders, DSM-IV-TR substance dependence aside from cannabis or tobacco,
contraindications for NAC treatment, or recent synthetic cannabinoid use were excluded.
Recruitment, conducted between January 2014 and April 2015, occurred primarily through
community media advertisements. Interested individuals were prescreened by phone, and
those meeting general entry criteria were scheduled for consent and screening procedures in
the research clinic.
2.3 General Procedures

Author Manuscript

Details of study design have been described previously (McClure et al., 2014). All
procedures and data collection were conducted in research clinics at participating sites. At
the baseline visit, comprehensive psychiatric and substance use diagnostic assessments,
medical history and physical examination, and laboratory testing (urine pregnancy and drug
tests) were performed (Sheehan et al., 1998; First et al., 2004). Timeline Follow-Back
methods were used to assess self-reported substance use (Sobell et al., 1988; Mariani et al.,
2011).

Author Manuscript

Eligible participants were enrolled in a CM intervention, and randomized to medication
treatment group. Participants were seen twice weekly during the 12-week treatment phase
and a follow-up post-treatment assessment was conducted 4 weeks after treatment
conclusion. During one weekly visit, the study medical clinician provided medical
management and adverse event assessment, participants completed self-assessments, and
UCT and CM procedures were completed. The other weekly visit was brief, consisting only
of UCT and CM procedures. At multiple time points, participants and medical clinicians
were asked to state whether they thought the participant was receiving NAC or placebo, to
evaluate penetration of the blind. Upon the first negative UCT for a participant, the sample
was additionally sent for synthetic cannabinoid testing (Soft Landing Labs, Elmhurst IL) to
confirm that the participant was not substituting synthetic cannabinoids for traditional
cannabis.
2.4 Interventions

Author Manuscript

2.4.1 Medication—Participants were randomized to a double-blind 12-week course of
orally administered NAC 1200 mg or placebo twice daily. Randomization, conducted
centrally through the CTN Data and Statistics Center, was on a 1:1 ratio, with stratification
by study site and self-reported binary tobacco smoking status (yes/no), in light of prior
research indicating poorer cannabis cessation outcomes among tobacco users (Haney et al.,
2013; Peters et al., 2014).
United States Pharmacopeia grade NAC powder was encapsulated in 600 mg quantities (two
600 mg capsules per twice-daily dose). Matched placebo capsules were also prepared.
Riboflavin 25 mg was added to all capsules (100 mg/day total) as a biomarker for
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medication adherence (assessed fluorometrically by the Clinical Neurobiology Laboratory,
Medical University of South Carolina, Charleston SC) (Malcolm et al., 2000). All capsules
were packaged in blister packs, dispensed weekly, with individual labels for time/date of
each dose.

Author Manuscript

2.4.2 Embedded Behavioral Treatment—All participants received CM twice weekly
during treatment, including escalating schedules of cash reinforcement with resets, targeting
(a) visit attendance (initial attended visit $10, escalating by $2 per subsequent visit, and reset
to $10 after a missed visit; maximum $30 per visit), and (b) cannabis abstinence, confirmed
by urine dipstick test (initial abstinent visit $5, escalating by $2 per subsequent visit, and
reset to $5 after a non-abstinent or missed visit; maximum $25 per visit). Medical
management, a low-intensity supportive intervention emphasizing cannabis abstinence,
medication adherence, and study retention, was conducted by the medical clinician weekly
throughout treatment (Volpicelli et al., 2001). This intervention was selected to closely
match psychosocial procedures in the prior adolescent trial, and to reflect care that could be
delivered in real-world medical settings.
2.5 Outcomes
2.5.1 Efficacy—UCT (<50 ng/mL considered negative) measured by the central laboratory
during weekly clinic visits and at post-treatment follow-up, was conducted as the primary
biological measure of cannabis use.
2.5.2 Safety/Tolerability—Adverse events were assessed at all study visits, including
severity and relatedness to study drug or study procedures. Vital signs monitoring and urine
pregnancy testing were additionally conducted.

Author Manuscript

2.5.3 Adherence—Pre-defined criteria for medication adherence included taking ≥80% of
prescribed study medication per study week (assessed via weekly medication diaries and
blister pack pill counts), confirmed by urine riboflavin level >1500 ng/mL, after subtracting
pre-randomization riboflavin level (Herron et al., 2013).
2.6 Statistical Analyses

Author Manuscript

The primary study hypothesis was that participants randomized to NAC would be more
likely than those randomized to placebo to have negative UCTs during treatment. An intentto-treat approach including all randomized participants was used. All missing UCTs (missed
visit/dropout/lost-to-follow-up) were imputed as positive, a method that does not make the
missing-at-random assumption and has been employed in substance use disorder treatment
trials (Avants et al., 2000; Bickel et al., 1988; Budney et al., 2006; Johnson et al., 2007;
Trivedi et al., 2017; Winhusen et al., 2014). A sensitivity analysis using various single
imputation approaches was also performed to evaluate the impact of various deviations from
the missing-at-random assumption. The scenarios included imputing missing UCTs as
negative, using surrounding UCTs to impute missing intermittent UCTs, and the worst-case
scenarios in which the UCT result is imputed based on treatment assignment (i.e., all
missing UCTs in the NAC group imputed as positive and all those in the placebo group
imputed as negative, and vice-versa).
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Based on findings from the prior adolescent trial, in which cannabis abstinence rates varied
from 20% to 50% in the placebo arm, and consideration of a 6-site model, a sample size of
300 was determined to provide 80% power to detect an odds ratio of 2 at the two-sided 5%
level of significance for the primary outcome, as well as evaluation of 2- and 4-week end-oftreatment abstinence outcomes, which were judged as clinically important for evaluation.

Author Manuscript

For the primary outcome measure, a repeated-measures logistic regression model was used
to evaluate the odds of a negative UCT as an indicator of abstinence across all 12 weeks of
treatment. At each week, the primary outcome was an indicator of whether the UCT at that
visit was negative (<50 ng/mL). Because each participant contributed up to 12 outcomes to
the model, generalized estimating equations (GEEs) were used to adjust for this correlation
(Liang and Zeger, 1986). The primary longitudinal model included the main effects of
treatment, time, site, and baseline tobacco smoking, as well as a time-by-treatment
interaction. Testing of the treatment difference evaluated the overall treatment effect by
considering the average treatment effect over all time points via a Score test. Any variables
in this model that were not statistically significant were dropped from all further analyses.
Wald-based odds ratios (OR) and asymptotic 95% confidence intervals (CI) were computed.
Efficacy analyses were repeated within the subgroup of participants meeting pre-defined
criteria for medication adherence. Pre-specified secondary analyses examined whether
abstinence rates differed across clinical sites, baseline tobacco use status, sex, ethnicity,
and/or race, and whether these variables were effect modifiers for the relationship between
NAC and abstinence.

Author Manuscript

Pre-specified logistic regression models were used to analyze the odds of cannabis
abstinence over 2- and 4-week end-of-treatment periods and at the post-treatment follow-up
visit. GEEs were used to test for differences in the proportion of self-reported days using
throughout treatment.
All statistical analyses were conducted using SAS version 9.3 or higher (SAS Institute Inc.
Cary, NC, USA). Significance was set at a 2-sided p-value of 0.05.

3. Results
3.1 Enrollment and Baseline Characteristics

Author Manuscript

Of 626 individuals formally screened, 302 met criteria and were randomized (Figure 1 –
CONSORT Diagram). Baseline demographics and clinical characteristics are presented in
Table 1; the randomization groups did not differ in these key variables, aside from education
(p=0.037) and employment status (p=0.004). Baseline urine cannabinoid levels were higher
in this sample than in the prior adolescent trial (1075.1 ± SD 1430.1 versus 417.0 ± SD
522.3 ng/mL, p<0.0001). Additionally, participants in this sample had used cannabis 15.1 ±
SD 9.2 years, compared to 4.2 ± SD 1.8 years in the prior adolescent trial (p<0.0001). In the
30 days prior to initial assessment, participants in this sample had used cannabis on 26.0 ±
SD 6.2 days, compared with 23.1 ± SD 6.1 days in the prior adolescent study (p<0.0001)
(Gray et al., 2012).
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The proportion of negative UCTs in the NAC and placebo groups at each visit (intent-totreat sample) is illustrated in Figure 2. While there was a significant effect of time on
abstinence (p=0.001), there was no statistically significant difference between the NAC and
placebo groups in the average odds of cannabis abstinence over time (OR=1.00, 95% CI:
0.63–1.59, p=0.984). Overall, 22.3% of UCTs in the NAC group were negative, compared
with 22.4% in the placebo group. The proportion of missing UCTs at study visit ranged from
12% at week 1 to 32% at week 12, resulting in 23% of all expected UCTs being imputed. Of
the various missing data scenarios considered in the sensitivity analysis, only the two worstcase scenarios of imputation by treatment assignment yielded statistically significant
treatment differences (p<0.001). For all other scenarios, the p-values were greater than 0.8.
End-of-treatment and post-treatment analyses, as well as comparisons of self-reported
cannabis use, similarly yielded no statistically significant evidence that NAC and placebo
differentially affected abstinence. All tests for synthetic cannabinoids (n=107) were
negative.
Subgroup analyses: While there was no clinical site by treatment interaction (p=0.429), site
was a non-significant trend-level predictor of cannabis abstinence (p=0.054). Baseline
tobacco smoking status was a strong indicator of cannabis outcomes, with tobacco smokers
being half as likely as non-tobacco smokers to achieve cannabis abstinence during treatment
(OR=0.52, 95% CI: 0.31–0.88, p=0.008), but there was no tobacco-by-treatment interaction
(p=0.883) (Figure 3). Sex was not a significant predictor of cannabis abstinence, and there
was no sex-by-treatment interaction. Hispanic/Latino participants were half as likely as nonHispanic/Latino participants to test negative for cannabinoids during treatment (OR=0.52,
95% CI: 0.27–1.00, p=0.030), but there was no ethnicity-by-treatment interaction (p=0.881).

Author Manuscript

For analyses of race, three participants were excluded: two who refused to report their race
and one whose race was unknown. Further, to optimize power, only two groups were used:
White participants (n=176) and racial minority participants (n=123). The latter category
included Black/African American (n=84), multiracial (n=19), Asian (n=3), American Indian/
Alaskan Native (n=2), Native Hawaiian/Pacific Islander (n=1), and Other (n=14). There was
a trend-level race-by-treatment interaction, suggesting that while racial minority participants
had overall lower proportions of negative UCTs, they differentially responded more
favorably to NAC than to placebo (White NAC versus PBO OR=0.81, 95% CI: 0.46–1.44;
racial minority NAC versus PBO OR=1.97, 95% CI: 0.84–4.63; race-by-treatment
interaction p=0.083) (Figure 4). There was no association between race and tobacco
smoking status (p=0.757).

Author Manuscript

The study’s primary outcome measure was examined post-hoc within participants ages 18–
21 (n=35 in the NAC group and n=23 in the placebo group), overlapping with the prior
adolescent trial’s age range of 15–21. While the small sample size notably limited statistical
power, within this age group NAC participants, compared to placebo participants, had
numerically (but not statistically significantly) doubled rates of abstinence (OR=2.03, 95%
CI: 0.70–5.86, p=0.187), a magnitude consistent with that noted in the prior adolescent trial
(Gray et al., 2012).
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3.3 Safety/Tolerability
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Adverse events were generally infrequent, without clinically significant between-group
differences in the rates of overall or specific events. In sum, 26.8% of NAC participants and
34.2% of placebo participants reported any treatment-emergent adverse events. Of the 7
reported serious adverse events, 6 occurred in the placebo group and 1 occurred in the NAC
group, and none were deemed to have a causal relationship with study medication. Body
mass index, heart rate, and blood pressure did not change significantly over time, regardless
of treatment group.
3.4 Blinding, Retention, and Adherence

Author Manuscript

Among participants assigned to NAC, 46.5% guessed they were receiving NAC and 53.5%
guessed they were receiving placebo, and the medical clinician guessed that 52% were
receiving NAC and 48% were receiving placebo. Among those assigned to placebo, 53.7%
guessed they were receiving NAC and 46.3% guessed they were receiving placebo, and the
medical clinician guessed that 57.3% were receiving NAC and 42.7% were receiving
placebo. These differences were not statistically significant, and the participant and medical
clinician agreed on guesses more often than by chance (p<0.0001).
Among randomized participants, 71.9% in the NAC group and 68.5% in the placebo group
were retained through the end of active treatment. Availability of the primary outcome
measure (UCT) generally mirrored weekly visit attendance, decreasing gradually over time,
with 68.6% in the NAC group and 67.1% in the placebo group available at the end-oftreatment visit.

Author Manuscript

Attendance-based contingent compensation (maximum possible total $610) was received by
95.4% of NAC participants (mean total $428, median $550) and 94.6% of placebo
participants (mean total $435, median $580). Abstinence-based contingent compensation
(maximum possible total $490) was received by 35.3% of NAC participants (mean total $86,
median $0) and 35.6% of placebo participants (mean total $71.80, median $0).

Author Manuscript

Following the pre-specified criteria for medication adherence, only a small subset of
participants (n=31 in the NAC group and n=26 in the placebo group) was deemed adherent.
Post-hoc examination of adherence based only on pill counts and self-report (taking ≥80%
of expected medication ≥80% of the 12 weeks, regardless of riboflavin testing results),
yielded n=87 NAC participants and n=78 placebo participants meeting criteria. The primary
efficacy outcome was analyzed in exploratory fashion within these small, underpowered
subgroups meeting adherence criteria, revealing no significant differential outcomes by
treatment group. Pill counts and self-report indicated that 73% of dispensed NAC doses and
72% of dispensed placebo doses were taken, compared to 95% and 93% taken in the prior
adolescent trial (Gray et al., 2012).

4. Discussion
This is the largest-enrollment and first national multisite pharmacotherapy RCT for CUD,
demonstrating the feasibility of executing these methods to evaluate candidate CUD
treatments. The present results yielded no statistically significant evidence that NAC 1200
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mg twice daily is differentially efficacious compared to placebo, when added to CM, for
cannabis cessation among adults with CUD. This contrasts with the significant positive
findings yielded in a similarly-designed prior trial in adolescents with CUD (Gray et al.,
2012). In the present trial, 22.3% of UCTs in the NAC group and 22.4% in the placebo
group were negative, compared to 40.9% and 27.2%, respectively, in the prior adolescent
trial. Response to NAC for CUD may potentially be age-dependent, with adolescents
benefiting, and adults not yielding benefit at the 1200 mg twice daily dose. Whether this
may be due to developmental differences in the course and phenomenology of CUD and
cumulative cannabis exposure, differential effects of NAC based on stages of brain
development, potential need for dose adjustment based on age, and/or other factors remains
unclear, and is deserving of further examination. It is notable that participants in the present
study presented with higher dosing, frequency, and chronicity of cannabis use compared to
those in the prior adolescent trial.

Author Manuscript
Author Manuscript

White participants had higher placebo response rates than racial minority participants,
possibly reflecting previously observed racial differences in response to CM (Montgomery
et al., 2012, 2015). Racial minority participants’ poorer response to CM may have allowed
NAC effects to emerge, as suggested by a two-fold NAC versus placebo difference in
abstinence outcomes. Without a known biological mechanism to explain a race by treatment
interaction, it is possible that race served as a proxy for socioeconomic or other demographic
factors. Regardless of treatment group, participants who self-reported as tobacco smokers at
baseline were less successful than non-tobacco smokers in achieving cannabis abstinence
during study participation. This relationship, consistent with prior research, demonstrates
that this may be a particularly challenging group to treat (Haney et al., 2013; Peters et al.,
2014). Hispanic/Latino participants were also less likely to achieve cannabis abstinence
during treatment than non-Hispanic/Latino participants. Further work is needed to address
racial and ethnic disparities in CUD treatment outcomes, and to enhance outcomes among
individuals with co-occurring tobacco use.
The present study included CM, a powerful behavioral treatment platform. Attendancebased CM likely contributed to study retention, and may be employed in future trials.
Response to abstinence-based CM, particularly notable among White participants, may have
obscured potential NAC versus placebo effects. It may be that adults with CUD (particularly
White adults) are more responsive to abstinence-based CM than adolescents, leaving less
opportunity for a complementary pharmacotherapy to provide added benefit. To date, NAC
has not been tested in CUD in a randomized placebo-controlled trial without a CM platform.

Author Manuscript

While the present study included a number of strengths in design and execution, findings
must be considered in light of limitations. While participant retention was high, medication
adherence was poorer than in the prior adolescent trial, notably compromising the potential
to test for efficacy in adults. Additionally, overall abstinence rates were low, especially for a
trial that included high-magnitude CM cash rewards for abstinence, potentially reflective of
the challenging nature of treating CUD and/or reflective of a particularly treatmentrefractory sample. It may be that a sample with less chronicity and frequency of cannabis
use would yield greater variance and thus greater potential for detecting between-group
differences in outcomes. Another limitation is that approximately 23% of the expected
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UCTs were missing due to missed visits, droupout, and loss to follow-up. Single imputation
approaches were implemented under varying assumptions about the degree of deviation
from the missing-at-random assumption with no changes in conclusion except in the most
extreme circumstances. While this approach allows non-ignorable missingness, the single
imputation approach treats imputed values as observed and thus may underestimate the true
variance.

Author Manuscript

CUD is a significant health problem with few efficacious treatments, yielding overall modest
outcomes. Across RCTs of psychosocial and pharmacological treatments for CUD, most
participants fail to achieve and sustain abstinence (Marshall et al., 2014; Gates et al., 2016).
More work is needed to develop novel treatments to enhance outcomes, particularly among
racial and ethnic minorities and among those with co-occurring tobacco use. Additionally,
medication adherence should be more reliably enhanced and monitored, potentially via
smartphone-delivered text prompts and video capture of medication-taking (Molton et al.,
2016; Peterson et al., 2016). While the present study does not refute NAC’s position as the
only pharmacotherapy with positive intent-to-treat efficacy findings in adolescents with
CUD (a finding in need of replication), it does demonstrate that, with the present dosing and
embedded CM treatment in both arms, there is no statistically significant evidence that NAC
is efficacious in adults with CUD.

5. Conclusions

Author Manuscript

Results suggest that prior efficacy results for NAC added to CM in adolescents may not
extend to adults with CUD. In light of these discrepant findings, a replication trial of NAC in
adolescents with CUD is indicated. Additional work is needed to identify and optimize novel
treatments for CUD, to enhance medication adherence in pharmacotherapy trials, and to
understand developmental and health-disparity factors that may influence differential CUD
treatment outcomes by age, ethnicity, and race.
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Highlights
•

N-acetylcysteine (NAC) was evaluated for cannabis use disorder (CUD) in
adults

•

All trial participants concurrently received contingency management (CM)

•

NAC was previously shown to be efficacious when added to CM in
adolescents

•

The present trial did not yield evidence of efficacy of NAC added to CM in
adults

•

Additional work is needed to identify and optimize novel treatments for CUD
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Figure 1.

CONSORT Diagram
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Figure 2.

Intent-to-treat urine cannabinoid test results BL=Baseline; NAC=N-acetylcysteine

Author Manuscript
Author Manuscript
Drug Alcohol Depend. Author manuscript; available in PMC 2018 August 01.

Gray et al.

Page 16

Author Manuscript
Author Manuscript
Figure 3.

Baseline tobacco use status and intent-to-treat urine cannabinoid test results BL=Baseline;
NAC=N-acetylcysteine
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Figure 4.

Race and intent-to-treat urine cannabinoid test results BL=Baseline; NAC=N-acetylcysteine
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